22/09/2026 Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease AbbVie’s RINVOQ® received EU approval for children with active pJIA Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe systemic sjögren's disease (Ref) Amgen’s Ph3 OASIZ 301 trial of dazodalibep (CD40L antagonist) met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in systemic disease

29/07/2026 AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo AbbVie announced European Commission approval of RINVOQ® for severe alopecia areata Johnson & Johnson announced a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for autoimmune diseases AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo (Ref) AbbVie announced that the European Commission (EC) approved RINVOQ® (upadac

17/07/2026 European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU Novartis received FDA traditional approval for Fabhalta® for the treatment of primary IgAN European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU (Ref) Boehringer Ingelheim announced that the European Commission had granted marketing authorization for JASCAYD® (nerandomilast; PDE4B inhibitor) for the treatment of adults with idiopathic pulmonary fibr

29/06/2026 Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with Non-segmental Vitiligo Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with severe alopecia areata Zura Bio exceeded Phase 2 enrollment target for HS and SSc and expanded tibulizumab program Dianthus Therapeutics announced the initiation of a Phase 3 trial of claseprubart in gMG Abivax announced ABETACT maintenan

12/02/2026 The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis ( Ref ) The European Commission approved Amgen’s Uplizna®(inebilizumab; anti-CD19 mAb) as an add-on treatment to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (M